Grünenthal GmbH
Acronym: Grünenthal
General Information
Identification Code: 67826544528-01
Website: [object Object]
Entity Form: Gesellschaft mit beschränkter Haftung
Registration Category: Companies & groups
Registration Date: 11/14/2010
Last Update: 1/18/2024
EP Accredited Number: 0
Mission & Interests
Goals: Grünenthal is a global leader in pain management and related diseases. As a science-based, privately-owned pharmaceutical company, we have a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide. Our purpose is to change lives for the better – and innovation is our passion. We are focusing all of our activities and efforts on moving towards our vision of a world free of pain.
As a science-based, privately-owned pharmaceutical company, we have a long track record of bringing innovative treatments and state-of-the-art technologies to people living with pain worldwide. Strong ongoing partnerships with leading healthcare and development organisations bring our new products to life. We’re a fully integrated pharmaceutical company that offers support along the entire value chain – from drug development through to commercialisation.
Grünenthal is headquartered in Aachen, Germany, and has affiliates in 29 countries across Europe.
Interests Represented: Promotes their own interests or the collective interests of their members
Interests:
- Competition
- Digital economy and society
- Employment and social affairs
- Humanitarian aid and civil protection
- Institutional affairs
- Public health
- Regional policy
- Research and innovation
Levels of Interest:
- global
- european
Activities
Main EU Legislative Proposals: Grünenthal's interests in Brussels deal with issues related to health- and pain care, pharmaceuticals, innovation, research and intellectual property. Grünenthal is a member of the European Federation of Pharmaceutical Industries and Associations (EFPIA) and therefore involved in following main legislative proposals and policies:
Pharmaceutical strategy, Review of incentives and rewards, Europe’s Beating Cancer plan, Regulation on Health Technology Assessments, Regulation to create an EU Health Emergency Response Authority (HERA) , Regulation on a European Health Data Space, Cross-border healthcare, Mental Health policy
Communication Activities: Grünenthal is dedicated to creating a better future for pain patients, so getting involved with diverse initiatives that support this goal is vital.
For example, Grünenthal supports the multi-stakeholder platform Societal Impact of Pain (SIP) which initiates projects, arranges events with policy maker and releases position paper on following topics:
- EU Health Policy topics like EU Cancer Plan / Mental Health
- Employment and social integration of patients such as European Pillar of social Rights
- Pain and digital medicine / eHealth / telehealth policies
You find an overview of our initiatives here: https://www.grunenthal.com/about-us/initiatives
Inter-institutional or Unofficial Groupings: Unofficial groupings
Head Office
Address: Zieglerstraße, 6
Post Code: D-52078
City: Aachen
Country: GERMANY
Phone: [object Object]
EU Office
Address: Zieglerstraße, 6
Post Code: D-52078
City: Aachen
Country: GERMANY
Phone: [object Object]
Financial Data
New Organisation: false
Closed Year: [object Object]
Current Year: [object Object]
Membership Information
Members10 Percent: 1
Members25 Percent: 0
Members50 Percent: 0
Members75 Percent: 0
Members: 1
Members F T E: 0.10000000149011612
Structure
Structure Type: Structure
Is Member Of: Societal Impact of Pain (SIP) https://www.sip-platform.eu/en
Organisation Members: Grünenthal is a member of the European Federation of Pharmaceutical Industries and Associations (EFPIA): http://www.efpia.eu as well as of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA): https://www.ifpma.org/ and has signed their respective codes.
Grünenthal is a sponsor the Societal Impact of Pain (SIP) platform. More info can be found here: https://www.sip-platform.eu